Official announcements from Quantum Leap Healthcare Collaborative. For media enquiries or to request additional information, contact us below.
For interview requests, assets, or background on QLHC's trials and programs.
Quantum Leap Healthcare Collaborative announced the appointment of three distinguished leaders to its Board of Directors. Dr. Janet Woodcock, former Acting Commissioner of the FDA, brings decades of regulatory expertise; Dorian Daley and Keir Loiacano bring legal, governance, and industry experience. The appointments strengthen QLHC's leadership as it expands its adaptive trial portfolio and data infrastructure.
QLHC announced that vepdegestrant (ARV-471), a novel PROTAC® estrogen receptor degrader being co-developed by Arvinas and Pfizer, will be evaluated in the I-SPY endocrine program. The addition expands the trial's investigation of next-generation endocrine therapies for hormone receptor-positive breast cancer and reflects QLHC's continued role as a hub for biopharma partnerships within adaptive platform trials.
Quantum Leap Healthcare Collaborative announced the mobile-responsive launch of Metastatic Trial Search (MTS), its clinical trial matching service for patients with metastatic breast cancer. The update expands MTS's reach to patients accessing the service via mobile devices, improving equity of access for underrepresented populations. MTS is powered by CTMatch, QLHC's second-generation trial matching platform.
Additional press releases will be added here as they become available. Each entry follows the same format: date, category, title, one-paragraph summary, and link to the full release.
For press kit materials, high-resolution imagery, spokesperson availability, or background on QLHC's trials and programs, contact info@qlhc.org. A full media package including organizational backgrounder, trial fact sheets, and leadership bios is in development.
